A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax® and ProAir® HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asthma

This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to help adult and adolescent subjects 12 years of age and older with persistent asthma to improve lung function.

Inclusion Criteria:

• Must provide written informed consent,
• Be between 12 years of age and older,
• Male or Female, females of non-child bearing potential or using reliable contraception
• Asthma for at least 6 months, FEV1 (forced expiratory volume in 1 second) between 50-80% of predicted value, and reversibility greater than or equal to 15% following 180 mcg albuterol
• Stable low dose of Inhaled Corticosteroids
• Non-smoker, 12 months smoking-free and <=10-pack years history
• Otherwise healthy
• Other criteria apply

Exclusion Criteria:

• Pregnant
• Allergic to albuterol or severe milk protein allergy
• Must not be on another trial for 30days.
• Other criteria apply